CIK 0001653087 · Accelerated filer<br>Smaller reporting company
Alector, Inc.
Sign in to watch- Ticker
- ALEC
- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- FY end
- Dec 31
- Entity type
- operating
- EIN
- 822933343
- Phone
- 415-231-5660
- Business address
- 131 OYSTER POINT BLVD., SUITE 600, SOUTH SAN FRANCISCO, CA, 94080
- Former names
- Alector LLC
- 4 Open-market sale Chief Medical Officer sold 14,892 shares at $2.52 ($37,519)
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 144 Insider Sale of Securities
- 8-K Event Exit or restructuring costs · Regulation FD disclosure
- 8-K Event Material agreement · New debt or obligation · Regulation FD disclosure
- SC 13G/A Stake Amended Statement of Ownership
- SC 13G/A Stake Amended Statement of Ownership
- 10-Q Report Quarterly Report
- 8-K Event Results of operations
- 4 Grant or award Director acquired 15,833 shares (grant or award)
- 4 Grant or award Chief Financial Officer acquired 216,400 shares (grant or award)
- 4 Grant or award President and Head of R&D acquired 300,000 shares (grant or award)
- 4 Grant or award Chief Executive Officer acquired 610,500 shares (grant or award)
- 4 Grant or award Chief Medical Officer acquired 184,380 shares (grant or award)
- 4 Open-market sale Chief Financial Officer sold 7,297 shares at $4.88 ($35,620)
- 4 Open-market sale Chief Executive Officer sold 26,499 shares at $4.88 ($129,387)
- 4 Open-market sale President and Head of R&D sold 13,926 shares at $4.88 ($67,981)
- 4 Open-market sale Chief Medical Officer sold 8,478 shares at $4.88 ($41,385)
Page 9 of 32 · 631 filings